Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials

Vedolizumab immunogenicity was assessed using an enzyme-linked immunosorbent assay (ELISA) with ~ 0.5 ug / mL drug disorders, which may underestimate the on-drug immunogenicity. We aimed to compare the results between ELISA and immunogenicity of a new drug-tolerant electrochemiluminescence (ECL) assay (and two versions of neutralizing tests, drug-sensitive to the drug-tolerant). ECL assay drug tolerance […]

Continue Reading